Eprotirome for the Treatment of Dyslipidemia, Efficacy and Safety 12-Week, Phase ii Study to Assess the Safety and Efficacy of KB2115 in Patients With Primary Hypercholesterolemia

NCT00776321 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

142

Enrollment

INDUSTRY

Sponsor class

Conditions

Primary Hypercholesterolemia

Interventions

DRUG: Eprotirome
DRUG: Placebo

Sponsor

Karo Bio AB